• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

信号肽选择性切割或氨肽酶介导的蛋白水解片段生成的 CXCL8 形式的生物学活性。

Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation.

机构信息

The Laboratory of Molecular Immunology, Department of Microbiology & Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium.

出版信息

PLoS One. 2011;6(8):e23913. doi: 10.1371/journal.pone.0023913. Epub 2011 Aug 31.

DOI:10.1371/journal.pone.0023913
PMID:21904597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3164136/
Abstract

BACKGROUND

Posttranslational modification of chemokines is one of the mechanisms that regulate leukocyte migration during inflammation. Multiple natural NH(2)-terminally truncated forms of the major human neutrophil attractant interleukin-8 or CXCL8 have been identified. Although differential activity was reported for some CXCL8 forms, no biological data are available for others.

METHODOLOGY/PRINCIPAL FINDINGS: Aminopeptidase-cleaved CXCL8(2-77) and CXCL8(3-77), the product of alternative cleavage of the signal peptide CXCL8(-2-77) and the previously studied forms containing 77 and 72 amino acids, CXCL8(1-77) and CXCL8(6-77), were prepared by solid-phase peptide synthesis, purified and folded into active proteins. No differences in binding and calcium signaling potency were detected between CXCL8(1-77), CXCL8(-2-77), CXCL8(2-77) and CXCL8(3-77) on cells transfected with one of the human CXCL8 receptors, i.e. CXCR1 and CXCR2. However, CXCL8(-2-77) was more potent compared to CXCL8(1-77), CXCL8(2-77) and CXCL8(3-77) in signaling and in vitro chemotaxis of peripheral blood-derived human neutrophils. Moreover, CXCL8(-2-77) was less efficiently processed by plasmin into the more potent CXCL8(6-77). The truncated forms CXCL8(2-77) and CXCL8(3-77) had higher affinity for heparin than CXCL8(1-77), a property important for the presentation of CXCL8 on endothelial layers. Upon intraperitoneal injection in mice, elongated, truncated and intact CXCL8 were equally potent to recruit neutrophils to the peritoneal cavity.

CONCLUSIONS

In terms of their ability to induce neutrophil recruitment in vivo, the multiple CXCL8 forms may be divided in three groups. The first group includes CXCL8 proteins consisting of 75 to 79 amino acids, cleaved by aminopeptidases, with intermediate activity on neutrophils. The second group, generated through proteolytic cleavage (e.g. by Ser proteases), contains 69 to 72 amino acid forms which are highly potent neutrophil attractants in vivo. A third category is generated through the modification of the arginine in the NH(2)-terminal region into citrulline by peptidylarginine deiminases and has weak potency to induce neutrophil extravasation.

摘要

背景

趋化因子的翻译后修饰是调节炎症期间白细胞迁移的机制之一。已经鉴定出主要人中性粒细胞趋化因子白细胞介素-8 或 CXCL8 的多种天然 NH2-末端截断形式。虽然报道了一些 CXCL8 形式的差异活性,但其他形式没有生物学数据。

方法/主要发现:通过固相肽合成、纯化和折叠成活性蛋白来制备氨基肽酶切割的 CXCL8(2-77)和 CXCL8(3-77)、信号肽 CXCL8(-2-77)的替代切割产物和之前研究的包含 77 和 72 个氨基酸的形式,CXCL8(1-77)和 CXCL8(6-77)。在转染一种人 CXCL8 受体(即 CXCR1 和 CXCR2)的细胞上,CXCL8(1-77)、CXCL8(-2-77)、CXCL8(2-77)和 CXCL8(3-77)之间在结合和钙信号转导效力方面没有差异。然而,与 CXCL8(1-77)、CXCL8(2-77)和 CXCL8(3-77)相比,CXCL8(-2-77)在信号转导和体外趋化性方面对人外周血中性粒细胞更有效。此外,CXCL8(-2-77)被纤溶酶更有效地加工成更有效的 CXCL8(6-77)。截短形式 CXCL8(2-77)和 CXCL8(3-77)比 CXCL8(1-77)对肝素具有更高的亲和力,这一特性对于 CXCL8 在血管内皮层的呈现很重要。在小鼠的腹腔内注射中,延长的、截断的和完整的 CXCL8 同样能够将中性粒细胞募集到腹腔中。

结论

就其在体内诱导中性粒细胞募集的能力而言,多种 CXCL8 形式可分为三组。第一组包括由氨基肽酶切割的 75 到 79 个氨基酸的 CXCL8 蛋白,对中性粒细胞具有中等活性。第二组通过蛋白水解切割(例如通过丝氨酸蛋白酶)产生,包含 69 到 72 个氨基酸的形式,在体内是高度有效的中性粒细胞趋化因子。第三类是通过肽基精氨酸脱亚氨酶将 NH2-末端区域的精氨酸修饰为瓜氨酸产生的,对诱导中性粒细胞渗出的作用较弱。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/e996fb3c10c3/pone.0023913.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/a0a695b70504/pone.0023913.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/f3caa5b8e681/pone.0023913.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/7c90b5529f7e/pone.0023913.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/4813c92f27d1/pone.0023913.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/53bf3ba15ed1/pone.0023913.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/e996fb3c10c3/pone.0023913.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/a0a695b70504/pone.0023913.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/f3caa5b8e681/pone.0023913.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/7c90b5529f7e/pone.0023913.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/4813c92f27d1/pone.0023913.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/53bf3ba15ed1/pone.0023913.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1092/3164136/e996fb3c10c3/pone.0023913.g006.jpg

相似文献

1
Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation.信号肽选择性切割或氨肽酶介导的蛋白水解片段生成的 CXCL8 形式的生物学活性。
PLoS One. 2011;6(8):e23913. doi: 10.1371/journal.pone.0023913. Epub 2011 Aug 31.
2
Truncation of CXCL8 to CXCL8(9-77) enhances actin polymerization and in vivo migration of neutrophils.CXCL8 的截断形式 CXCL8(9-77) 增强了中性粒细胞的肌动蛋白聚合和体内迁移。
J Leukoc Biol. 2020 Jun;107(6):1167-1173. doi: 10.1002/JLB.3AB0220-470R. Epub 2020 Apr 9.
3
Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.CXCL8/白细胞介素-8 翻译后修饰对 CXCR1 和 CXCR2 内化及信号转导特性的差异影响。
Int J Mol Sci. 2018 Nov 27;19(12):3768. doi: 10.3390/ijms19123768.
4
A Requirement for Neutrophil Glycosaminoglycans in Chemokine:Receptor Interactions Is Revealed by the Streptococcal Protease SpyCEP.链球菌丝氨酸蛋白酶 SpyCEP 揭示了中性粒细胞糖胺聚糖在趋化因子:受体相互作用中的需求。
J Immunol. 2019 Jun 1;202(11):3246-3255. doi: 10.4049/jimmunol.1801688. Epub 2019 Apr 22.
5
Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors.探讨趋化因子 CXCL8 中 CXC 基序在高亲和力结合和激活 CXCR1 和 CXCR2 受体中的作用。
J Biol Chem. 2010 Sep 17;285(38):29262-9. doi: 10.1074/jbc.M110.146555. Epub 2010 Jul 14.
6
CXCL8((3-73))K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8.CXCL8((3 - 73))K11R/G31P可拮抗配体与中性粒细胞CXCR1和CXCR2受体的结合以及细胞对CXCL8/IL - 8的反应。
Biochem Biophys Res Commun. 2002 May 10;293(3):939-44. doi: 10.1016/S0006-291X(02)00318-2.
7
Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.CXCL8单体和二聚体对CXCR1和CXCR2的差异激活与调控
J Immunol. 2009 Sep 1;183(5):3425-32. doi: 10.4049/jimmunol.0900305. Epub 2009 Aug 10.
8
Heparin-bound chemokine CXCL8 monomer and dimer are impaired for CXCR1 and CXCR2 activation: implications for gradients and neutrophil trafficking.肝素结合趋化因子 CXCL8 单体和二聚体对 CXCR1 和 CXCR2 的激活作用受损:对梯度和中性粒细胞迁移的影响。
Open Biol. 2017 Nov;7(11). doi: 10.1098/rsob.170168.
9
Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.兔中性粒细胞趋化蛋白(NCP)可激活CXCR1和CXCR2,是人类CXCL6的功能同源物。
Biochem Pharmacol. 2004 Nov 15;68(10):1947-55. doi: 10.1016/j.bcp.2004.07.003.
10
Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.人源化形式的CXCR1/CXCR2拮抗剂,即牛CXCL8((3-74))K11R/G31P,可有效阻断ELR-CXC趋化因子活性及气道内毒素血症病理过程。
Int Immunopharmacol. 2007 Dec 15;7(13):1723-31. doi: 10.1016/j.intimp.2007.09.008. Epub 2007 Sep 29.

引用本文的文献

1
Heterogeneous neutrophils in lung transplantation and proteolytic CXCL8 activation in COVID-19, influenza and lung transplant patient lungs.肺移植中的异质性中性粒细胞以及新冠病毒、流感病毒感染和肺移植患者肺部中CXCL8的蛋白水解激活
Cell Mol Life Sci. 2024 Dec 3;81(1):475. doi: 10.1007/s00018-024-05500-z.
2
The Role of Chemokines in Obesity and Exercise-Induced Weight Loss.趋化因子在肥胖和运动诱导的体重减轻中的作用。
Biomolecules. 2024 Sep 4;14(9):1121. doi: 10.3390/biom14091121.
3
CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis.

本文引用的文献

1
Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity.蛋白酶或肽基精氨酸脱亚氨酶(PAD)对CXCL5氨基末端区域的翻译后修饰对其生物活性有不同影响。
J Biol Chem. 2010 Sep 24;285(39):29750-9. doi: 10.1074/jbc.M110.119388. Epub 2010 Jul 14.
2
NETs: a new strategy for using old weapons.NETs:旧武器的新策略。
Trends Immunol. 2009 Nov;30(11):513-21. doi: 10.1016/j.it.2009.07.011. Epub 2009 Aug 21.
3
Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation.
原发性骨髓纤维化中的 CXCL8 及其同源受体 CXCR1/CXCR2。
Haematologica. 2024 Jul 1;109(7):2060-2072. doi: 10.3324/haematol.2023.284921.
4
Cytokine gene polymorphisms implicated in the pathogenesis of infection outcome.细胞因子基因多态性与 感染结局的发病机制有关。
Front Immunol. 2024 Feb 9;15:1285411. doi: 10.3389/fimmu.2024.1285411. eCollection 2024.
5
Identification of a Salt Bridge That Is Functionally Important for Chemokine Receptor CXCR1 but not CXCR2.鉴定对趋化因子受体CXCR1具有功能重要性但对CXCR2没有功能重要性的盐桥。
ACS Pharmacol Transl Sci. 2023 Jul 14;6(8):1120-1128. doi: 10.1021/acsptsci.3c00070. eCollection 2023 Aug 11.
6
The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.趋化因子 CXCL8 和 CXCL12:分子和功能特性、在疾病中的作用以及药理学干预的努力。
Cell Mol Immunol. 2023 Mar;20(3):217-251. doi: 10.1038/s41423-023-00974-6. Epub 2023 Feb 1.
7
CXCL8 in Tumor Biology and Its Implications for Clinical Translation.肿瘤生物学中的CXCL8及其临床转化意义
Front Mol Biosci. 2022 Mar 15;9:723846. doi: 10.3389/fmolb.2022.723846. eCollection 2022.
8
From ELISA to Immunosorbent Tandem Mass Spectrometry Proteoform Analysis: The Example of CXCL8/Interleukin-8.从 ELISA 到免疫吸附串联质谱法蛋白质组分析:以 CXCL8/白细胞介素-8 为例。
Front Immunol. 2021 Mar 11;12:644725. doi: 10.3389/fimmu.2021.644725. eCollection 2021.
9
Amblyomma americanum serpin 27 (AAS27) is a tick salivary anti-inflammatory protein secreted into the host during feeding.美洲钝眼蜱丝氨酸蛋白酶抑制剂 27(AAS27)是一种在蜱类吸食宿主血液时分泌到宿主体内的抗炎症的唾液蛋白。
PLoS Negl Trop Dis. 2019 Aug 26;13(8):e0007660. doi: 10.1371/journal.pntd.0007660. eCollection 2019 Aug.
10
A C-terminal CXCL8 peptide based on chemokine-glycosaminoglycan interactions reduces neutrophil adhesion and migration during inflammation.基于趋化因子-糖胺聚糖相互作用的 C 端 CXCL8 肽可减少炎症期间中性粒细胞的黏附和迁移。
Immunology. 2019 Jun;157(2):173-184. doi: 10.1111/imm.13063.
CXCL8 的瓜氨酸化增加了这种趋化因子将中性粒细胞动员到血液循环中的能力。
Haematologica. 2009 Oct;94(10):1346-53. doi: 10.3324/haematol.2009.006973. Epub 2009 Jul 16.
4
Chapter 1. Isolation, identification, and production of posttranslationally modified chemokines.第1章. 翻译后修饰趋化因子的分离、鉴定及生产
Methods Enzymol. 2009;461:3-29. doi: 10.1016/S0076-6879(09)05401-9.
5
The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity.趋化因子的达菲抗原受体转运趋化因子并支持其促迁移活性。
Nat Immunol. 2009 Jan;10(1):101-8. doi: 10.1038/ni.1675. Epub 2008 Dec 7.
6
Regulation of chemokine activity by posttranslational modification.通过翻译后修饰对趋化因子活性的调控。
Pharmacol Ther. 2008 Nov;120(2):197-217. doi: 10.1016/j.pharmthera.2008.08.006. Epub 2008 Aug 28.
7
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.肽基精氨酸脱亚氨酶对CXCL8的瓜氨酸化改变了受体的使用方式,阻止了蛋白水解,并减轻了组织炎症。
J Exp Med. 2008 Sep 1;205(9):2085-97. doi: 10.1084/jem.20080305. Epub 2008 Aug 18.
8
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.CD13/氨肽酶N对CXCL11的蛋白水解加工会损害CXCR3和CXCR7的结合及信号传导,并减少淋巴细胞和内皮细胞的迁移。
Blood. 2007 Jul 1;110(1):37-44. doi: 10.1182/blood-2006-10-049072. Epub 2007 Mar 15.
9
Neutrophil extracellular traps: casting the NET over pathogenesis.中性粒细胞胞外诱捕网:笼罩发病机制的“陷阱”
Curr Opin Microbiol. 2007 Feb;10(1):52-6. doi: 10.1016/j.mib.2006.12.005. Epub 2007 Jan 8.
10
How neutrophils kill microbes.中性粒细胞如何杀死微生物。
Annu Rev Immunol. 2005;23:197-223. doi: 10.1146/annurev.immunol.23.021704.115653.